2. Borson S., Scanlan J.M., Chen P., Ganguli M. The Mini-Cog as a screen for dementia: Validation in a population-based sample. J Am Geriatr Soc. 2003; 51(10): 1451–54. https://dx.doi.org/10.1046/j.1532-5415.2003.51465.x.

3. Harris M.I., Flegal K.M., Cowie C.C. et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care. 1998; 21(4): 518–24. https://dx.doi.org/10.2337/diacare.21.4.518.

4. Umegaki H. Type 2 diabetes as a risk factor for cognitive impairment: current insights. Clin Interv Aging. 2014; 9: 1011–19. https://dx.doi.org/10.2147/CIA.S48926.

5. Anstey K.J., Ashby-Mitchell K., Peters R. Updating the evidence on the association between serum cholesterol and risk of late-life dementia: Review and meta-analysis. J Alzheimers Dis. 2017; 56(1): 215–28. https://dx.doi.org/10.3233/JAD-160826.

6. Ghafar M.Z.A.A., Miptah H.N., O'Caoimh R. Cognitive screening instruments to identify vascular cognitive impairment: A systematic review. Int J Geriatr Psychiatry. 2019; 34(8): 1114–27. https://dx.doi.org/10.1002/gps.5136

7. Sachdev P., Kalaria R., O’Brien J. et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014; 28(3): 206–18. https://dx.doi.org/10.1097/WAD.0000000000000034.

8. Клинические рекомендации. Ишемический инсульт и транзиторная ишемическая атака у взрослых. Всероссийское общество неврологов, Национальная ассоциация по борьбе с инсультом, Ассоциация нейрохирургов России, межрегиональная общественная организация «Объединение нейроанестезиологов и нейрореаниматологов», общероссийская общественная организация «Союз реабилитологов России». Рубрикатор клинических рекомендаций Минздрава России. 2021. ID: 171. Доступ: https://cr.minzdrav.gov.ru/schema/171_2 (дата обращения – 01.05.2023).

9. Gorelick P.B., Scuteri A., Black S.E. Vascular contributions to cognitive impairment and dementia. A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011; 42(9): 2672–713. https://dx.doi.org/10.1161/STR.0b013e3182299496.

10. Hanon O., Pequignot R., Seux M.L. et al. Relationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaints. J Hypertens. 2006; 24(10): 2101–7. https://dx.doi.org/10.1097/01.hjh.0000244961.69985.05.

11. SPRINT MIND Investigators for the SPRINT Research Group; Williamson J.D., Pajewski N.M., Auchus A.P. et al. Effect of intensive vs standard blood pressure control on probable dementia: A randomized clinical trial. JAMA. 2019; 321(6): 553–61. https://dx.doi.org/10.1001/jama.2018.21442.

12. Risk reduction of cognitive decline and dementia: WHO guidelines. 2019. URL: https://www.who.int/publications/i/item/9789241550543 (date of access – 01.05.2023).

13. Ramirez A., Wolfsgruber S., Lange C. et al. Elevated HbA1c is associated with increased risk of incident dementia in primary care patients. J Alzheimers Dis. 2015; 44(4): 1203–12. https://dx.doi.org/10.3233/JAD-141521.

14. Song D., Yu D.S.F., Li P.W.C., Lei Y. The effectiveness of physical exercise on cognitive and psychological outcomes in individuals with mild cognitive impairment: A systematic review and meta-analysis. Int J Nurs Stud. 2018; 79: 155–64. https://dx.doi.org/10.1016/j.ijnurstu.2018.01.002.

15. Hill N.T., Mowszowski L., Naismith S.L. et al. Computerized cognitive training in older adults with mild cognitive impairment or dementia: A Systematic review and meta-analysis. Am J Psychiatry. 2017; 174(4): 329–40. https://dx.doi.org/10.1176/appi.ajp.2016.16030360.

16. Bennett S., Laver K., Voigt-Radloff S. et al. Occupational therapy for people with dementia and their family carers provided at home: A systematic review and meta-analysis. BMJ Open. 2019; 9(11): e026308. https://dx.doi.org/10.1136/bmjopen-2018-026308.

17. Doody R.S., Ferris S.H., Salloway S. et al. Donepezil treatment of patients with MCI: a 48week randomized, placebo-controlled trial. Neurology. 2009; 72(18): 1555–61. https://dx.doi.org/10.1212/01.wnl.0000344650.95823.03.

18. Winblad B., Gauthier S., Scinto L. et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology. 2008; 70(22): 2024–35. https://dx.doi.org/10.1212/01.wnl.0000303815.69777.26.

19. Feldman H.H., Ferris S., Winblad B. et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol. 2007; 6(6): 501–12. https://dx.doi.org/10.1016/S1474-4422(07)70109-6.

20. Kandiah N., Ong P.A., Yuda T. et al. Treatment of dementia and mild cognitive impairment with or without cerebrovascular disease: Expert consensus on the use of Ginkgo biloba extract, EGb 761®. CNS Neurosci Ther. 2019; 25(2): 288–98. https://dx.doi.org/10.1111/cns.13095.

21. Gauthier S., Schlaefke S. Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: A systematic review and meta-analysis of randomized placebo-controlled trials. Clin Interv Aging. 2014; 9: 2065–77. https://dx.doi.org/10.2147/CIA.S72728.

22. Guekht A.B., Moessler H., Novak P.H. et al. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. J Stroke Cerebrovasc Dis. 2011; 20(4): 310–18. https://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2010.01.012.

23. Herrmann W.M., Stephan K., Gaede K. et al. A multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia. Dement Geriatr Cogn Disord. 1997; 8(1): 9–17. https://dx.doi.org/10.1159/000106595.

24. Sha M.C., Callahan C.M. The efficacy of pentoxifylline in the treatment of vascular dementia: A systematic review. Alzheimer Dis Assoc Disord. 2003; 17(1): 46–54. https://dx.doi.org/10.1097/00002093-200301000-00006.

25. Nappi G., Bono G., Merlo P. et al. Long-term idebenone treatment of vascular and degenerative brain disorders of the elderly. Arch Gerontol Geriatr. 1992; 15(3): 261–69. https://dx.doi.org/10.1016/0167-4943(92)90061-8.

26. Cotroneo A.M., Castagna A., Putignano S. et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clin Interv Aging. 2013; 8: 131–37. https://dx.doi.org/10.2147/CIA.S38420.

27. Guekht A., Skoog I., Edmundson S. et al. ARTEMIDA trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A randomized controlled trial to assess the efficacy of Actovegin in poststroke cognitive impairment. Stroke. 2017; 48(5): 1262–70. https://dx.doi.org/10.1161/STROKEAHA.116.014321.

28. Михайлова Н.М., Селезнева Н.Д., Калын Я.Б. с соавт. Эффективность лечения Актовегином больных пожилого возраста с синдромом мягкого когнитивного снижения сосудистого генеза. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2013; 113(7–2): 69–76.

29. Государственный реестр лекарственных средств Минздрава России. Инструкция по медицинскому применению лекарственного препарата Мексидол. РУ: ЛП-№(000086)-(РГ-RU) от 12.10.2023. Доступ: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=9e354e6e-6abe-45cd-90be-a68e824b938b (дата обращения – 01.03.2024).

30. Государственный реестр лекарственных средств Минздрава России. Инструкция по медицинскому применению лекарственного препарата Глиатилин. РУ: П N011966/01 от 02.08.2023. Доступ: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=d99ef401-d3bb-47e7-9dda-e53852f7b7be (дата обращения – 01.03.2024).

31. Jin B.R., Liu H.Y. Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment: Systematic review and Bayesian network meta-analysis. Neural Regen Res. 2019; 14(5): 805–16. https://doi.org/10.4103/1673-5374.249228.

32. Государственный реестр лекарственных средств Минздрава России. Доступ: http://grls. rosminzdrav.ru (дата обращения – 01.03.2024).

33. Государственный реестр лекарственных средств Минздрава России. Инструкция по медицинскому применению лекарственного препарата Цераксон. РУ: ЛП-№(003254)-(РГ-RU) от 22.09.2023. Доступ: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c9689923-1fff-464e-a125-b6c5d9b67dc4 (дата обращения – 01.03.2024).

34. Guekht A., Skoog I., Edmundson S. et al. ARTEMIDA trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A randomized controlled trial to assess the efficacy of Actovegin in poststroke cognitive impairment. Stroke. 2017; 48(5): 1262–70. https://doi.org/10.1161/STROKEAHA.116.014321.40.

35. Государственный реестр лекарственных средств Минздрава России. Инструкция по медицинскому применению лекарственного препарата Глицин. РУ: ЛСР-001431/07 от 30.05.2023. Доступ: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=39cb67a1-406a-4125-9791-5e97b96b665f (дата обращения – 01.03.2024).